Navigation Links
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy,of BF-200 ALA In Actinic Keratosis

LEVERKUSEN, Germany - Biofrontera AG (DSE: B8F) announces today that it has received very positive results in the dose finding part of its phase IIb/III clinical trial started in autumn 2006. BF-200 ALA, a gel that combines the active substance 5-aminolevulinic acid (ALA) with the nanoemulsion BF-200, was strongly and significantly superior to placebo in the treatment of actinic keratosis. BF-200 ALA is used in photodynamic therapy, which eliminates tumor tissue through a combination of an active substance and the irradiation with red light.

The placebo-controlled, randomized and double-blind study was conducted in 13 clinical centers in Germany under the medical direction of Prof. Dr. Rolf-Markus Szeimies, University Clinics of Regensburg. To verify the efficacy of the compound, 105 patients were treated once by photodynamic therapy with one of three different ALA concentrations or placebo. Primary endpoint of the clinical trial was the percentage of the complete remission of actinic lesions. Since strong pain often occurs during photodynamic therapy with competitor products, the appearance of pain during the irradiation after BF-200 ALA application was also monitored.

When patients were evaluated 12 weeks after a single treatment with BF-200 ALA, at least 60-70 % of the treated lesions were completely cured, depending on the weighting of the clinical centers and the area of the head. Relevant side effects did not occur during the study, the cosmetic results were excellent. Only 6 % of the patients complained about strong pain. The 10% dose of the active compound ALA was superior to the other doses tested. Consequently, Biofrontera will conduct additional studies to verify the safety and efficacy of this concentration in preparation for its registration.

"This result impressively demonstrates the great potential of our development candidate BF-200 ALA. Every other person above 60 years of
'"/>




Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:3/3/2015)... Mass. , March 3, 2015 Boston Scientific ... Charles J. Dockendorff and Stephen P. MacMillan ... Two current members of the board, Uwe E. Reinhardt ... for re-election at the company,s annual meeting of stockholders in ... was formerly the executive vice president and chief financial officer ...
(Date:3/3/2015)... , March 3, 2015   Surefire ... a prospective clinical trial comparing the Surefire Infusion System ... either primary or metastatic liver cancer, using the ... uptake of embolic agents, and with significantly decreased ... presented today at the Society of Interventional ...
(Date:3/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/x5lz9r/global_poc ... POC Diagnostics Market 2015-2019" report to their offering. ... POC Diagnostics market to grow at a CAGR of ... POC diagnostics are IVD devices and tools used for ... The use of these devices helps in the rapid ...
Breaking Medicine Technology:Boston Scientific Elects Charles J. Dockendorff And Stephen P. MacMillan To Board Of Directors 2Clinical Trial Comparing the Surefire Infusion Device to an End Hole Catheter Finds Surefire Increases Tumor Uptake and Decreases Non-Target Embolization In Every Patient, Multiple Liver Cancer Types 2Global POC Diagnostics Market 2015-2019 with Abbott Labs, Alere, Bayer Healthcare, Danaher, F. Hoffmann-La Roche & Johnson & Johnson Dominating 2
... 2007 - Pro-Pharmaceuticals,Inc. (Amex: PRW), a developer ... Eliezer Zomer, Ph.D., Executive Vice,President, Product Development ... Advanced Solid Tumors of,5-FU with an Admixture ... of Oncodevelopmental Biology and Medicine,(ISOBM) Conference to ...
... Investigative Dermatology, FREEPORT, N.Y., May 16, 2007 ... clinical data that indicates,that OCTN-1 skin cells ... L-ergothioneine (EGT) as a protector against oxidative,damage, ... more powerful and,efficient antioxidant than idebenone, scavenging ...
Cached Medicine Technology:Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 2Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 3Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 4Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 5AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin,Cells Have the Ability to Recognize, Transport and Utilize,L-ergothioneine (EGT) As A Protector Against Oxidative Damage 2
(Date:3/3/2015)... 2015 The biggest name in indoor ... the world’s first fully integrated air quality platform that ... an air purifier to remove dust, pollen and hazardous ... control, via phone, tablet or computer. , Sweden’s Blueair, ... countries worldwide, will unveil its Internet-enabled air sensor together ...
(Date:3/3/2015)... SC (PRWEB) March 03, 2015 The ... the public’s expectation of excellence in care and safe ... the position of the RNS that biologic infusions are ... under the direct supervision of a registered nurse (RN), ... reactions, including anaphylaxis can occur in patients receiving these ...
(Date:3/3/2015)... 2015 In March, 1% for the ... kick off a new campaign, “Know Your Source,” which calls ... and ambassadors in their quest for ingredient awareness and better ... of its members and partners, including King Arthur Flour, Good ... to raise awareness for food as an environmental issue, with ...
(Date:3/3/2015)... The report “Alopecia – Pipeline Review, H1 2015? ... Alopecia is the loss of hair. Alopecia areata and ... Causes for alopecia include aging, genetics, illness, chemotherapy, malnutrition ... pattern hair loss, female diffuse hair loss, hairs easily ... focal or diffuse and by the presence or absence ...
(Date:3/3/2015)... US Air Purifiers LLC , an ... is pleased to announce that all Rabbit brand air purifiers ... to the west coast port strikes. This news comes just ... , The port strikes, which have caused ... quarter economic growth by as much as 1%, have hindered ...
Breaking Medicine News(10 mins):Health News:Smart sensor and air purifier interconnect to track and trap dust, pollen and dangerous particles in home and workplace air 2Health News:Administration of Biologic Infusions: A Position Statement of the Rheumatology Nurses Society 2Health News:1% For the Planet Asks Consumers to “Know Your Source” 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 2Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 3
... was halted early after risk of both recurrence and ... -- European researchers report more grim news concerning women ... run the risk of developing breast cancer while taking ... face a higher risk of a recurrence or a ...
... to be published in the American Journal of,Epidemiology, ... publication in the American Journal of Epidemiology, a team ... Michigan found,that women who ate the most fish (more ... pregnancies delivered children with the highest,scores on two cognitive ...
... year when more,than 1.5 million high school and college students ... large quantities of alcohol. Students who,vacation with friends over spring ... home with parents or relatives, according to a report in ... and Drugs., Instead of just telling students not to ...
... HILL, N.C., March 25 Successful brand leaders,know ... crucial and effective,strategies to optimize a product,s lifecycle., ... Promotion in,segmented sectors, and Clinical and Scientific Excellence ... a brand,s success and describes exactly,which costs need ...
... whites, study finds , , TUESDAY, March 25 (HealthDay News) -- ... blacks are much less likely to get colonoscopies than their ... who have an increased chance of developing colon cancer continue ... lack of a doctor referral stood out as the primary ...
... NEW YORK, March 25 For journalists covering,today,s release ... and,Medicare assessing the fiscal health of the government,s two ... budget),the authors of a popular book on the federal ... question: Are America,s leaders so immersed in,short term political ...
Cached Medicine News:Health News:HRT Raises Recurrence Risk Among Breast Cancer Survivors 2Health News:Study: Pregnant Women Who Eat More Fish, Including Canned Tuna, Have Smarter Children 2Health News:It's Spring Break: How Much Does Heavy Drinking Affect Your Body? 2Health News:Sales and Marketing Effectiveness in Pharmaceutical Companies Increases Brand Performance 2Health News:High-Risk Blacks Less Likely to Get Colonoscopies 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: